Pathogenesis of infantile haemangioma

British Journal of Dermatology

Volumn 169, Issue 1, 2013, Pages 12-19

  Greenberger, S ^a   Bischoff, J ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALPONIN; CD133 ANTIGEN; CD34 ANTIGEN; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE TRANSPORTER 1; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSIN; NEURAL GLIAL ANTIGEN 2; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROPRANOLOL; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ANGIOPOIETIN; MTOR PROTEIN, HUMAN; NOTCH RECEPTOR; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CAPILLARY HEMANGIOMA; CELL PROLIFERATION; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; MAST CELL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; EMBRYONIC STEM CELL; HEMANGIOMA; INFANT; PATHOLOGY; PHYSIOLOGY; SKIN NEOPLASMS; VASCULAR ENDOTHELIUM;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-ANTAGONISTS; ANGIOPOIETINS; EMBRYONIC STEM CELLS; ENDOTHELIUM, VASCULAR; HEMANGIOMA; HUMANS; INFANT; MAST CELLS; PROPRANOLOL; RECEPTOR, TIE-2; RECEPTORS, NOTCH; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879973820     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12435     Document Type: Review

References (85)

1. Takahashi K, Mulliken JB, Kozakewich HP, et al,. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357-64.
2. Bielenberg DR, Bucana CD, Sanchez R, et al,. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor IFN-beta. Int J Oncol 1999; 14: 401-8.
3. Boscolo E, Bischoff J,. Vasculogenesis in infantile hemangioma. Angiogenesis 2009; 12: 197-207.
4. Pack GT, Miller TR,. Hemangiomas; classification, diagnosis and treatment. Angiology 1950; 1: 405-26.
5. Malan E,. Vascular Malformations (Angiodysplasias). Milan: Carlo Erba Foundation, 1974, 4.
6. Kaplan E,. Vascular malformations of extremities. In: Symposium on Vascular Malformations and Melanotic Lesions. (, H Williams, ed), St Louis, MO: Mosby, 1983, 144-61.
7. Smoller BR, Apfelberg DB,. Infantile (juvenile) capillary hemangioma: a tumor of heterogeneous cellular elements. J Cutan Pathol 1993; 20: 330-6.
8. Khan ZA, Boscolo E, Picard A, et al,. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118: 2592-9.
9. Boscolo E, Stewart CL, Greenberger S, et al,. JAGGED1 signaling regulates hemangioma stem cell-to-pericyte/vascular smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 2011; 31: 2181-92.
10. Xu D, O TM, Shartava A, et al,. Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. J Hematol Oncol 2011; 4: 54.
11. Mai HM, Zheng JW, Wang YA, et al,. CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma. Chinese Med J 2013; 126: 88-94.
12. Itinteang T, Tan ST, Brasch H, et al,. Primitive mesodermal cells with a neural crest stem cell phenotype predominate proliferating infantile haemangioma. J Clin Pathol 2010; 63: 771-6.
13. Itinteang T, Vishvanath A, Day DJ, et al,. Mesenchymal stem cells in infantile haemangioma. J Clin Pathol 2011; 64: 232-6.
14. Itinteang T, Tan ST, Brasch HD, et al,. Infantile haemangioma expresses embryonic stem cell markers. J Clin Pathol 2012; 65: 394-8.
15. Adepoju O, Wong A, Kitajewski A, et al,. Expression of HES and HEY genes in infantile hemangiomas. Vasc Cell 2011; 3: 19.
16. Höpfel-Kreiner I,. Histogenesis of haemangiomas-an ultrastructural study on capillary and cavernous hemangiomas of the skin. Pathol Res Pract 1980; 170: 70-90.
17. North PE, Waner M, Mizeracki A, et al,. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22.
18. Mulliken JB, Glowacki J,. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69: 412-22.
19. Folkman J, Haudenschild C,. Angiogenesis in vitro. Nature 1980; 288: 551-6.
20. Dosanjh A, Chang J, Bresnick S, et al,. In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol 2000; 27: 441-50.
21. Boye E, Yu Y, Paranya G, et al,. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001; 107: 745-52.
22. Yu Y, Flint AF, Mulliken JB, et al,. Endothelial progenitor cells in infantile hemangioma. Blood 2004; 103: 1373-5.
23. Yuan SM, Jiang HQ, Ouyang TX, et al,. [The distribution and evolution of pericytes in infantile hemangioma.] Zhonghua zheng xing wai ke za zhi 2007; 23: 322-4 (in Chinese).
24. Wu JK, Adepoju O, De Silva D, et al,. A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Angiogenesis 2010; 13: 15-23.
25. Yuan SM, Chen RL, Shen WM, et al,. Mesenchymal stem cells in infantile hemangioma reside in the perivascular region. Pediatr Dev Pathol 2012; 15: 5-12.
26. Boscolo E, Mulliken JB, Bischoff J,. Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1. Arterioscler Thromb Vasc Biol 2013; 33: 501-9.
27. Glowacki J, Mulliken JB,. Mast cells in hemangiomas and vascular malformations. Pediatrics 1982; 70: 48-51.
28. Tan ST, Wallis RA, He Y, et al,. Mast cells and hemangioma. Plast Reconstr Surg 2004; 113: 999-1011.
29. Biswas A, Richards JE, Massaro J, et al,. Mast cells in cutaneous tumors: innocent bystander or maestro conductor? Int J Dermatol 2013. (in press)
30. Boon LM, Ballieux F, Vikkula M,. Pathogenesis of vascular anomalies. Clin Plast Surg 2011; 38: 7-19.
31. Walter JW, Blei F, Anderson JL, et al,. Genetic mapping of a novel familial form of infantile hemangioma. Am J Med Genet 1999; 82: 77-83.
32. Grimmer JF, Williams MS, Pimentel R, et al,. Familial clustering of hemangiomas. Arch Otolaryngol Head Neck Surg 2011; 137: 757-60.
33. Walter JW, North PE, Waner M, et al,. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosom Cancer 2002; 33: 295-303.
34. Jinnin M, Medici D, Park L, et al,. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008; 14: 1236-46.
35. Frieden IJ, Reese V, Cohen D,. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996; 132: 307-11.
36. Stockman A, Boralevi F, Taieb A, et al,. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 2007; 214: 40-5.
37. Siegel DH, Shieh JT, Kwon EK, et al,. Copy number variation analysis in 98 individuals with PHACE syndrome. J Invest Dermatol 2013; 133: 677-84.
38. Bautch VL,. VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harbor Perspect Med 2012; 2: a006452.
39. Chang J, Most D, Bresnick S, et al,. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg 1999; 103: 1-9; discussion 10.
40. Kleinman ME, Greives MR, Churgin SS, et al,. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007; 27: 2664-70.
41. Greenberger S, Boscolo E, Adini I, et al,. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010; 362: 1005-13.
42. Greenberger S, Adini I, Boscolo E, et al,. Targeting NF-kappaB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 2010; 13: 327-35.
43. Zhang L, Lin X, Wang W, et al,. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg 2005; 116: 200-4.
44. Boscolo E, Mulliken JB, Bischoff J,. VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2011; 179: 2266-77.
45. Eichmann A, Simons M,. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol 2012; 24: 188-93.
46. Picard A, Boscolo E, Khan ZA, et al,. IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma. Pediatr Res 2008; 63: 263-7.
47. Augustin HG, Koh GY, Thurston G, et al,. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-77.
48. Koh GY,. Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol Med 2013; 19: 31-9.
49. Wouters V, Limaye N, Uebelhoer M, et al,. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010; 18: 414-20.
50. Limaye N, Wouters V, Uebelhoer M, et al,. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009; 41: 118-24.
51. Yu Y, Varughese J, Brown LF, et al,. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001; 159: 2271-80.
52. Perry BN, Govindarajan B, Bhandarkar SS, et al,. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 2006; 126: 2316-22.
53. Calicchio ML, Collins T, Kozakewich HP,. Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol 2009; 174: 1638-49.
54. Phng LK, Gerhardt H,. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16: 196-208.
55. Laplante M, Sabatini DM,. mTOR signaling in growth control and disease. Cell 2012; 149: 274-93.
56. Phung TL, Eyiah-Mensah G, O'Donnell RK, et al,. Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res 2007; 67: 5070-5.
57. Guba M, von Breitenbuch P, Steinbauer M, et al,. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
58. Hammill AM, Wentzel M, Gupta A, et al,. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57: 1018-24.
59. Greenberger S, Yuan S, Walsh LA, et al,. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 2011; 131: 2467-76.
60. Medici D, Olsen BR,. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS ONE 2012; 7: e42913.
61. Isik FF, Rand RP, Gruss JS, et al,. Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 1996; 61: 71-6.
62. Ritter MR, Dorrell MI, Edmonds J, et al,. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 2002; 99: 7455-60.
63. Ritter MR, Moreno SK, Dorrell MI, et al,. Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol 2003; 1: 291-9.
64. O TM, Tan M, Tarango M, et al,. Differential expression of SKI oncogene protein in hemangiomas. Otolaryngol Head Neck Surg 2009; 141: 213-18.
65. Kraling BM, Razon MJ, Boon LM, et al,. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 1996; 148: 1181-91.
66. Smadja DM, Mulliken JB, Bischoff J,. E-selectin mediates stem cell adhesion and formation of blood vessels in a murine model of infantile hemangioma. Am J Pathol 2012; 181: 2239-47.
67. Itinteang T, Brasch HD, Tan ST, et al,. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg 2011; 64: 759-65.
68. Youmbissi TJ, Tedong F, Fairbank ST, et al,. Plasma renin activity studies in a group of African neonates and children. J Trop Pediatr 1990; 36: 128-30.
69. Ma X, Zhao T, Xiao Y, et al,. Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. Eur J Pediatr 2013; 172: 653-9.
70. Christou EM, Wargon O,. Effect of captopril on infantile haemangiomas: a retrospective case series. Australas J Dermatol 2012; 53: 216-8.
71. Zarem HA, Edgerton MT,. Induced resolution of cavernous hemangiomas following prednisolone therapy. Plast Reconstr Surg 1967; 39: 76-83.
72. Cohen SR, Wang CI,. Steroid treatment of hemangioma of the head and neck in children. Ann Otol Rhinol Laryngol 1972; 81: 584-90.
73. Greenberger S, Bischoff J,. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harbor Perspect Med 2011; 1: a006460.
74. Rössler J, Haubold M, Gilsbach R, et al,. β-1 Adrenoceptor mRNA level reveals distinctions between infantile hemangioma and vascular malformations. Pediatr Res 2013; 73: 409-13.
75. Chisholm KM, Chang KW, Truong MT, et al,. beta-Adrenergic receptor expression in vascular tumors. Mod Pathol 2012; 25: 1446-51.
76. Hadaschik E, Scheiba N, Engstner M, et al,. High levels of beta2-adrenoceptors are expressed in infantile capillary hemangiomas and may mediate the therapeutic effect of propranolol. J Cutan Pathol 2012; 39: 881-3.
77. Doshi BS, Kulkarni RD, Dattani KK, et al,. Effect of labetalol and propranolol on human cutaneous vasoconstrictor response to adrenaline. Int J Clin Pharmacol Res 1984; 4: 25-8.
78. Fredriksson JM, Lindquist JM, Bronnikov GE, et al,. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta-adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem 2000; 275: 13802-11.
79. Lutgendorf SK, Cole S, Costanzo E, et al,. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003; 9: 4514-21.
80. Park SY, Kang JH, Jeong KJ, et al,. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. Int J Cancer 2013; 128: 2306-16.
81. Ji Y, Chen S, Li K, et al,. The role of beta-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div 2013; 8: 1.
82. Guo K, Ma Q, Wang L, et al,. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009; 22: 825-30.
83. Shi M, Liu D, Duan H, et al,. Catecholamine up-regulates MMP-7 expression by activating AP-1 and STAT3 in gastric cancer. Mol Cancer 2010; 9: 269.
84. Nilsson MB, Armaiz-Pena G, Takahashi R, et al,. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 2007; 282: 29919-26.
85. Wong L, Nation RL, Chiou WL, et al,. Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy. Br J Clin Pharmacol 1979; 8: 163-7.